表紙
市場調查報告書

腫瘤學的價格與償付

Pricing and Reimbursement in Oncology

出版商 FirstWord 商品編碼 940411
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
腫瘤學的價格與償付 Pricing and Reimbursement in Oncology
出版日期: 2020年03月05日內容資訊: 英文
簡介

本報告提供全球腫瘤學的價格及償付的相關調查,美國和歐洲的付款者的態度及需求,應對製藥公司付款者的疑慮可採取的實際次序等相關的資訊。

目錄

主題的摘要

調查手法和目的

  • 調查手法
  • 目的

主要的洞察的摘要

課題與洞察

  • 價格和償付的評價標準
    • 課題概要
    • 疑問點
    • 重要的洞察
    • 支支持性提及 等
  • 患者接診方案
  • 抗癌劑的合理價格
  • 標靶治療和搭配診斷
  • 查核點抑制劑
  • CAR-T細胞療法
  • 不定腫瘤類型療法
  • 腫瘤學的生物相似藥的影響
  • 今後的醫藥品開發
  • 腫瘤學中創新的支付模式的機會
目錄
Product Code: 596201555

Payers want pharma to address the challenges they face

Specialised cancer therapies such as checkpoint inhibitors have significantly improved outcomes for patients but for payers they represent a growing funding challenge, especially as triple and quadruple oncology therapy becomes common place. To achieve the widest possible access to patients, pharma needs payers positively on board, so what must developers do to get payer support for their oncology product pricing and reimbursement ambitions? Understanding the pressures and touchpoints that resonate with payers is critical. In this report, US and European payers reveal their attitudes and needs and the practical steps pharma can take to address their concerns.

Table of Contents

Subject synopsis

Research methodology and objectives

  • Methodology
  • Objectives

Key insights summary

Issues and insights

  • Assessment criteria for pricing and reimbursement
    • Issue summary
    • Questions
    • Key insights
    • Supporting quotes
  • Patient access schemes
    • Issue summary
    • Questions
    • Key insights
    • Supporting quotes
  • Fair pricing for cancer drugs
    • Issue summary
    • Questions
    • Key insights
    • Supporting quotes
    • Intelligence exhibits
  • Targeted therapies and companion diagnostics
    • Issue summary
    • Questions
    • Key insights
    • Supporting quotes
  • Checkpoint inhibitors
    • Issue summary
    • Questions
    • Key insights
    • Supporting quotes
    • Intelligence exhibits
  • CAR-T cell therapies
    • Issue summary
    • Questions
    • Key insights
    • Supporting quotes
    • Intelligence exhibits
  • Tumour agnostic therapy
    • Issue summary
    • Questions
    • Key insights
    • Supporting quotes
  • The impact of biosimilars in oncology
    • Issue summary
    • Questions
    • Key insights
    • Supporting quotes
    • Intelligence exhibits
  • Future drug development
    • Issue summary
    • Questions
    • Key insights
    • Supporting quotes
  • Opportunities for innovative payment models in oncology
    • Issue summary
    • Questions
    • Key insights
    • Supporting quotes
    • Intelligence exhibits